ARCHIVES

Reimbursement Of Some Anticancer Drugs Expected To Drop Sharply Under HHS Policy.

This article is from The Cancer Letter archive.

Vol. 26 No. 26 | June 30, 2000

Download PDF Visit The Full Archive

Related Articles

Sanofi Responds to Criticism From Oncologists

November 8, 2012

Regulatory Agencies: FDA Proposes “Treatment IDE” Funding Opportunities:

February 7, 1997

In Brief: DeVita, FDA Chief Help Kill California Bill Legalizing Laetrile Wit committee Testimony

August 26, 1977

Genetic Testing: No Easy Answers To Public Questions

May 15, 1998

New Guidelines Developed For Cancer Control Granters For Community Outreach

June 4, 1976

NCI Clarifies P01 Grant Application Dates

September 13, 1996